Real-World Assessment of Switching from a Dipeptidyl Peptidase-4 Inhibitor to Exenatide Once-Weekly in Patients with Type 2 Diabetes

被引：0
|
作者：
Gorgojo-Martinez, Juan J.
Gargallo-Fernandez, Manuel A.
Brito-Sanfiel, Miguel A.
Lisbona-Catalan, Arturo
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1118-P
引用
收藏
页码：A297 / A297
页数：1
相关论文
共 50 条
  • [21] Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis
    Evans, M.
    Husain, M.
    Frenkel, O.
    Mangla, K.
    Srivastava, A.
    Lingvay, I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S416 - S416
  • [22] Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis
    Husain, M.
    Evans, M.
    Frenkel, O.
    Mangla, K. K.
    Srivastava, A.
    Lingvay, I.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1939 - 1939
  • [23] Comparing the Real-World Effects of Once-Weekly Semaglutide and Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcomes, Health Care Resource Utilization, and Medical Costs in Individuals With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
    de Havenon, Adam H.
    Tan, Xi
    Liang, Yuanjie
    Yedigarova, Larisa
    Noone, Josh
    Xie, Lin
    Inzucchi, Silvio E.
    STROKE, 2024, 55
  • [24] ACHIEVEMENT OF DIABETES-RELATED QUALITY MEASURES IN PATIENTS TREATED WITH EXENATIDE ONCE-WEEKLY IN A REAL-WORLD SETTING
    Singhal, M.
    Schauerhamer, M.
    Wittbrodt, E.
    Unni, S.
    Hurd, J.
    McAdam-Marx, C.
    VALUE IN HEALTH, 2017, 20 (05) : A164 - A164
  • [25] Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus
    Addy, Carol
    Tatosian, Daniel
    Glasgow, Xiaoli S.
    Gendrano, Isaias N., III
    Kauh, Eunkyung
    Martucci, Ashley
    Johnson-Levonas, Amy O.
    Selverian, Diana
    Matthews, Catherine Z.
    Gutierrez, Marie
    Wagner, John A.
    Stoch, S. Aubrey
    CLINICAL THERAPEUTICS, 2016, 38 (03) : 516 - 530
  • [26] Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes
    Imprialos, Konstantinos P.
    Stavropoulos, Konstantinos
    Doumas, Michael
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25): : 2502 - 2502
  • [27] Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
    Garcia de Lucas, Maria Dolores
    Pablo Miramontes-Gonzalez, Jose
    Aviles-Bueno, Beatriz
    Isabel Jimenez-Millan, Ana
    Rivas-Ruiz, Francisco
    Perez-Belmonte, Luis M.
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [28] Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study
    Inagaki, Nobuya
    Sano, Hiroki
    Seki, Yoshifumi
    Kuroda, Shingo
    Kaku, Kohei
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (02) : 354 - 359
  • [29] Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes
    Stein, Stephanie A.
    Lamos, Elizabeth M.
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (04) : 599 - 608
  • [30] Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Tiwari, Atul
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (10) : 1091 - 1104
12345